Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13195MR)

This product GTTS-WQ13195MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hyperlipidemia research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13195MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11405MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ12283MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ2573MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ3797MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ4483MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ10426MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ13999MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ9997MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KRN-23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW